Palmitoyl Tetrapeptide-7 vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | Palmitoyl Tetrapeptide-7 | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Mechanism | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |